Dr. Godbout is well-known leader of biotechnology. From April 1, 2000 to October 2009, Dr. Godbout was the Founder, President & CEO of Genome Canada, a private, not-for-profit Corporation, dedicated to investing and implementing a national strategy in genomics and proteomics research in Canada. Dr Godbout was named President and General Manager of Société Innovatech Québec, a $60 million technology investment fund May 1994 to May 1997. From May 1, 1997, Dr. Godbout was the Senior Vice-President of BioCapital, a Canadian venture capital firm specializing in seed-to-mezzanine stage private financing of companies demonstrating strong potential in the healthcare and biotechnology sectors. 

In March 2006, Dr. Godbout was shortlisted by the editors of Nature Biotechnology, as one of twenty nominees who have made the most remarkable and influential contribution to biotech in the past ten years in the category “Biobusiness in the rest of the world”. Dr. Godbout is presently a member of the board of directors of several Canadian biopharmaceutical companies, foundations and scientific Canadian organizations such as Acasti Pharma, AmorChem, AngioChem, AsmaCure, MethylGene (chairman since 2010, assisted with sale), Génome Québec (chairman), BioContact, BioQuébec FQRS, Montréal In Vivo et la Fondation de l’ataxie de Charlevoix. Dr. Godbout has been a member of the Board of the “Conseil de la Science et de la Technologie du Québec” from 1996 to 2004 and of the National Science and Engineering Research Council of Canada from 1999 to 2002. Dr Godbout is an Officer of the Order of Canada, which is given to only the most accomplished Canadians.  

Dr. LeBlanc has recently retired as Vice President, Learning, Research and Innovation at Capital Health where he headed the research and education initiatives.  Dr. LeBlanc, senior ophthalmologist and glaucoma specialist, was a professor and head of the Department of Ophthalmology and Visual Sciences at Dalhousie University from 1979 to 2003. He is well known both nationally and internationally for his work as leader of the Dalhousie Glaucoma Research Team. Over the past decade, Dr LeBlanc has been active in spearheading initiatives to develop new models of vision care both provincially and nationally. He chaired the National Coalition for Vision Health from 1999 to 2004 and is a past president of the Canadian Ophthalmological Society and the Canadian Glaucoma Society. He has also been a board member of a number of international glaucoma societies. In 2005, he was awarded the Order of Canada. His investiture as a member of the Order of Canada is a testimony to his broad perspectives in dealing with vision health issues in Canada. Dr Leblanc is a Member of the Order of Canada, which is given to only the most accomplished Canadians.

Dr. Clement serves as a Business Development Partner at Montreal-based AmorChem Ventures. John Co-Founded iCo Therapeutics Inc. and served as its Chief Technical & Development Officer and Chief Business Officer. Dr. Clement possesses over twenty years of experience in preclinical and clinical drug development, project management, and product acquisition. Dr. Clement served as Director, Business Development at QLT Inc., one of Canada's largest biotechnology companies and developer of Visudyne©, a $450M+ USD product targeting age-related macular degeneration. Dr. Clement served as Director, Extramural Research / Associate Director, Biochemical Pharmacology & Toxicology at Biochem Pharma a pioneer of the AIDS drug 3TC, research scientist & manager with Department of National Defence (DND) and Research Scientist with CIBA-Geigy Canada Ltd. During his tenure with DND he held various scientific leadership/management positions and was responsible for the development of a new antidote for nerve agent poisoning (HI-6). He served as Director of iCo Therapeutics Inc. Chairman of the Board of a 400 hundred bed hospital in Medicine Hat Alberta and elected Alderman in City of Medicine Hat.